Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in IntangiblesChange in IntangiblesChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Free Cash Flow (2016 - 2026)

Cytosorbents filings provide 15 years of Free Cash Flow readings, the most recent being -$4.9 million for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 131.16% to -$4.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was -$12.5 million, a 13.13% increase, with the full-year FY2025 number at -$12.5 million, up 13.13% from a year prior.
  • Free Cash Flow hit -$4.9 million in Q4 2025 for Cytosorbents, down from -$2.6 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of -$1.5 million in Q2 2025 to a low of -$9.1 million in Q4 2021.
  • Median Free Cash Flow over the past 5 years was -$4.8 million (2024), compared with a mean of -$4.8 million.
  • Biggest five-year swings in Free Cash Flow: tumbled 648.71% in 2021 and later surged 67.85% in 2025.
  • Cytosorbents' Free Cash Flow stood at -$9.1 million in 2021, then skyrocketed by 40.66% to -$5.4 million in 2022, then decreased by 19.99% to -$6.5 million in 2023, then soared by 67.18% to -$2.1 million in 2024, then tumbled by 131.16% to -$4.9 million in 2025.
  • The last three reported values for Free Cash Flow were -$4.9 million (Q4 2025), -$2.6 million (Q3 2025), and -$1.5 million (Q2 2025) per Business Quant data.